Article Text

PDF
Palliative care in mesothelioma: Are current services RESPECT-able enough?
  1. Neelam Kumar1,
  2. Doraid Alrifai1,
  3. Ioannis Psallidas2
  1. 1 Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK
  2. 2 Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
  1. Correspondence to Dr Ioannis Psallidas, Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford OX37LP, UK; ioannis.psallidas{at}ndm.ox.ac.uk

Statistics from Altmetric.com

Malignant pleural mesothelioma (MPM) remains a devastating disease with a poor prognosis; median survival ranges from just 8 to 14 months from diagnosis.1 The incidence is the highest in the UK and Australia and while this is expected to peak by 2020, the global incidence is predicted to increase for several decades particularly in emerging economies. Treatment options remain limited. Chemotherapy using third-generation antifolate agents is the only treatment modality that has been shown to improve survival in MPM.2 Standard first-line treatment is combination pemetrexed and cisplatin (or carboplatin), however response rates to these regimens are low. An evaluation of over 1700 patients who received pemetrexed with either cisplatin or carboplatin demonstrated response rates of 26.3% and 21.7%, respectively.3 Surgical management is controversial with a lack of robust randomised trial data. Novel treatments are however on the horizon. The genomic era has led to the early development of precision therapies, and as with several other cancers, immunotherapy may hold promise.4

Alongside a paucity of current effective treatments, patients with MPM are also subject to a high symptom burden. In a study of 495 patients,5 92% reported three or more symptoms at diagnosis with fatigue (94%), dyspnoea (89%), chest pain (85%), appetite loss (87%) and cough (75%) being the most common. The psychological burden of a diagnosis of MPM can be equally distressing with patients reporting feelings of uncertainty and lack of control.6 Carers of patients with MPM similarly report an emotional and physical toll.7 Arguably, MPM is therefore the archetypal disease necessitating effective palliative care, defined by the WHO as ‘an approach that improves the quality of life of patients and their families facing life-threatening illness, through the prevention and relief of suffering by early identification and impeccable assessment and treatment of pain …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Lung cancer
    Fraser Brims Samal Gunatilake Iain Lawrie Laura Marshall Carole Fogg Cathy Qi Lorraine Creech Nicola Holtom Stephanie Killick Bernard Yung David Cooper Louise Stadon Peter Cook Elizabeth Fuller Julie Walther Claire Plunkett Andrew Bates Carolyn Mackinlay Anil Tandon Nicholas A Maskell Karen Forbes Najib M Rahman Stephen Gerry Anoop J Chauhan on behalf of the RESPECT-Meso investigators Andrew Bateman Melissa Dobson Richard Hopgood Samuel King Angela Morgan Stephen Morris Alice Mortlock Neal Navani Anna Nowak Michael Peake Mark Roberts Lynne Squibb Paul Taylor